Search

for
Search:

Did you mean FDA Adverse Event Reporting System?

Glossary FDA Adverse Event Reporting System

database tracking drug and biologic safety issues post-marketing

The FDA Adverse Event Reporting System (FAERS) is a database managed by the U.S. Food and Drug Administration that collects information on adverse events and medication errors reported by healthcare professionals, consumers, and manufacturers. This system helps the FDA monitor the safety of drugs and biologics after they are marketed, ensuring that any potential risks are identified and managed appropriately.

Related Terms

Research

5 / 1000+ results

research Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)

January 2026 in “Nutrición Hospitalaria”

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System

research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)

April 2020 in “Sleep”

In this study, data from the FAERS database indicated varied associations between certain medications and obstructive sleep apnea, with some biologics associated with a decreased risk of developing the condition.

Finasteride Is Associated With a Higher Odds of Obstructive Sleep Apnea: Results From the US FDA Adverse Events Reporting System

research 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)

1 citations , April 2018 in “Sleep”

This study found that finasteride use was associated with significantly higher odds of obstructive sleep apnea and insomnia compared to other medications.

Suicidal Behaviors (Suicidal Ideation, Suicide Attempt and Completed Suicide) in Patients Treated with Finasteride for Hair Loss: Results from the U.S. FDA Adverse Event Reporting System Database

research Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database

August 2018 in “Journal of The American Academy of Dermatology”

Real-World Study of Adverse Events Associated with Gepant Use in Migraine Treatment Based on the VigiAccess and U.S. Food and Drug Administration’s Adverse Event Reporting System Databases

research Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases

25 citations , July 2024 in “Frontiers in Pharmacology”

Gepant medications for migraines show varied safety profiles in this study, with specific adverse events reported across systems like gastrointestinal and skin disorders, highlighting the need for tailored treatment and monitoring.

View more "u s fda adverse event reporting system" in research →

Community Join

5 / 1000+ results

community U.S Court let Merck hide secrets about Finasteride.

in Finasteride/Dutasteride 303 upvotes 3 years ago

Hair loss discussion involving finasteride's side effects and effectiveness. Users shared mixed experiences, with some reporting side effects and others seeing positive results.

community Whoever had success with PYRILUTAMIDE, please give us hope outside of 5AR inhibitors.

in Product 8 upvotes 2 years ago

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

community Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)

44 upvotes 3 months ago

Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.

community Warning: Minoxidil usage around pets

in Minoxidil 454 upvotes 1 year ago

Minoxidil is highly toxic to pets, especially cats and dogs, even in small amounts. Many users have switched to oral minoxidil to prevent accidental exposure to their pets.

community Is there a topical androgen receptor blocker so we don't have to fuck with the enzyme and destroy our allopregnanolone, but go and hit the end target straight?

in Treatment 44 upvotes 2 years ago

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

View more "u s fda adverse event reporting system" in community →

Learn

1 / 801 results

learn Overview

View more "u s fda adverse event reporting system" in learn →

Clinics

6 / 13 results

All 13 clinic results →

Experts

4 / 4 results